Despite the current limitations of conventional anti-HER2 therapies in the treatment of HER2-positive breast cancer patients, the efficacy of new-generation HER2-targeted drug–antibody conjugates has been demonstrated in tumors that express HER2, albeit at low levels. Here, ERBB2 is linked to breast carcinoma.